Comparative Pharmacology
Head-to-head clinical analysis: EMEND versus EMRELIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMEND versus EMRELIS.
EMEND vs EMRELIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective substance P/neurokinin 1 (NK1) receptor antagonist, which inhibits the binding of substance P in the emetic pathway.
Emrelis is a monoclonal antibody that inhibits the interaction between programmed cell death protein 1 (PD-1) and its ligands PD-L1 and PD-L2, thereby activating T-cell-mediated antitumor immune response.
125 mg orally once 1 hour before chemotherapy; then 80 mg orally once daily on Days 2 and 3.
100 mg subcutaneously once weekly.
None Documented
None Documented
9–13 hours (terminal) in healthy adults; clinically, this supports once-daily dosing. In patients with severe renal impairment (CrCl <30 mL/min), half-life is prolonged to ~16 hours.
12 hours (terminal); dosing interval adjusted in renal impairment (CrCl <30 mL/min)
Primarily metabolized; ~5% unchanged in urine, ~57% in feces as metabolites, ~32% in urine as metabolites. Renal elimination of parent drug is minimal.
Renal: 70% unchanged; fecal: 15%; biliary: 10%
Category C
Category C
Antiemetic
Antiemetic